ABSTRACT: We describe truncation and SAR studies to identify a pentapeptide that binds Cbl tyrosine kinase binding domain with a higher affinity than the parental peptide. The pentapeptide has an alternative binding mode that allows occupancy of a previously uncharacterized groove. A peptide library was used to map the binding site and define the interface landscape. Our results suggest that the pentapeptide is an ideal starting point for the development of inhibitors against Cbl driven diseases.
■ INTRODUCTION
The casitas B-lineage lymphoma (Cbl) family of proteins plays a fundamental role in controlling tyrosine kinase-coupled cellular signaling pathways. A family of multidomain proteins that functions as scaffold-type E3 ubiquitin ligases, Cbl proteins specialize in negatively regulating activated protein tyrosine kinases (PTKs). 1−5 The Cbl−PTK interaction is a phosphorylation driven event that involves direct interaction between the N-terminal tyrosine kinase binding domain (TKB) of Cbl with cognate phosphotyrosyl peptide motifs on PTKs. 6, 7 The E3 ubiquitin ligase activity is mediated by the RING finger domain adjacent to the TKB domain. A highly conserved linker region bridges the TKB and the RING domains and participates with the RING finger in physical interactions with E2 ubiquitin conjugating enzymes (UBCs). 8 Within the C-terminal half, a proline rich region (PRR) mediates binding of SH3 domaincontaining proteins, while induced tyrosine phosphorylation sites allow complexes with SH2 domain-containing proteins. These interactions underscore the scaffolding function of the C-terminal sequences in juxtaposing additional targets to Cbl. 9 Targets recruited to Cbl by the TKB domain or the C-terminal interactions are subjected to ubiquitination and negative regulation. From a biochemical standpoint, inhibitors specific to Cbl(TKB) could serve to prevent Cbl recruitment to PTKs and to decouple the PTK binding function from the C-terminal region-mediated scaffolding function.
Several groups have recently identified oncogenic Cbl mutations within the RING and linker regions that are associated with a subset of human myelomonocytic leukemias. 10−14 The mutant Cbl allele is typically duplicated in a copy number-neutral loss of heterozygosity referred to as acquired uniparental disomy (aUPD), which has suggested a potential gain-of-oncogenic function of oncogenic Cbl mutants. 15, 16 Clinically relevant Cbl mutations, where analyzed, result in the loss of E3 ligase function but with maintenance of the protein−protein interactions suggesting that E3-deficient oncogenic mutants acquire a scaffolding function to assemble abnormal signaling complexes to promote sustained PTK signaling. 17−20 Since Cbl(TKB) interacts with a large number of PTKs, targeting these enzymes for therapy of cancers driven by Cbl mutations is likely to be limited. On the other hand, a more elegant approach would be to target the mutant Cbl proteins themselves. 21, 22 Data from our lab and others suggest that the transforming capacity of Cbl mutants depends on PTK binding; inhibitors of the Cbl(TKB)−PTK interaction could provide a novel means to treat leukemias driven by Cbl(linker/ RING) mutations. 21, 22, 22 The ability to reversibly disrupt the Cbl(TKB)−PTK interaction could also serve as a chemical biological approach to disrupt the function of Cbl proteins and to boost physiological responses in which Cbl proteins play a negative regulatory role.
The systematic development of small molecule inhibitors (SMIs) that perturb protein−protein interactions is becoming more feasible for generating biochemical reagents and therapeutics. From a biochemical standpoint, these compounds can serve as valuable tools to dissect the complex signaling networks in cellular systems. SMIs enjoy several advantages over classical biochemical techniques (i.e., gene knockouts, silencing RNA, mutagenesis). The rapid nature of small molecule inhibition permits the investigation of interactions that occur at much faster time scales, a necessary feature when the real-time responses of cellular pathways are being considered. The tunable nature allows for titrated inhibition, as opposed to the simple on/off mechanism afforded by genetic methods. The reversible nature of small molecule inhibition allows one to disrupt an interaction, observe the response, and end the disruption to recapture the initial condition. Taken together, these attributes offer the ability to directly perturb cellular pathways at the protein level without altering the genetic background of the system. SMIs, therefore, can provide the resolution needed to describe the role of a domain-specific, protein−protein interaction within a given pathway.
■ RESULTS AND DISCUSSION
In view of the lack of Cbl(TKB) inhibitors and given their biological and clinical relevance, we undertook a peptidomimetic approach. The initial steps in the peptidomimetic design process include (1) identifying a natural ligand, (2) defining the minimal active sequence, and (3) identifying the key residues and their relative 3D arrangement required for activity. 23, 24 In this report, we used a combination of methods to identify an optimal Cbl(TKB)-binding lead sequence suitable for structureguided design. We report an unusual increase in the binding affinity through truncation of a 12-mer Cbl(TKB) binding peptide. We predicted that the pentapeptide (1, pYTPEP) and its parental 12-mer peptide (2, TLNSDGpYTPEPA) will have similar binding affinity for Cbl. Interestingly, the biochemical data showed that 1 had about 3-to 8-fold higher affinity for Cbl(TKB) compared to 2. Computational studies with 1 suggest that the N-terminus of the pentapeptide rotates to occupy a shallow groove adjacent to the previously defined binding site. Such an interaction is not feasible with the 12-mer peptide 2. We propose that this flexibility and reorientation are the source of the improved affinity of 1 compared to 2. In addition, a library of pentapeptides was used to map the binding interface and define the optimal conformation of the ligand (see Table S1 in Supporting Information for numbering of peptides).
On the basis of the available crystal structures (Figure 1 ), we generated a truncation peptide set by sequentially removing amino acids from each terminus. 25−27 We started with the 9-mer peptide sequences, as this was the longest sequence in which each residue could be assigned 3D coordinates based on the crystal structures. The truncation set was screened in silico against Cbl(TKB) to identify the smallest unit that retained binding affinity (Table S2 ). The binding energies were calculated using AutoDock Vina in single calculation mode. 28 Unexpectedly, truncating the peptide to include only the pYTPEP sequence (1) resulted in a slight increase in binding affinity. On the basis of this finding, we predicted that the truncated pentapeptide would exhibit comparable binding affinity and provide a reasonable lead compound for a peptidomimetic inhibitor design strategy ( Figure S1 ).
To test this hypothesis, we used a set of orthogonal techniques, viz., fluorescence polarization (FP), isothermal titration calorimetry (ITC), surface plasmon resonance (SPR) (see Supporting Information Table S3 and Figures S2 and S3) , and TKB domain pull-down experiments. We recently reported the development and miniaturization of a Cbl(TKB) FP assay for high throughput screening to identify Cbl(TKB) inhibitors. 29 Here, the FP assay was adapted to quantify binding of 12-mer peptide or pentapeptide to Cbl(TKB) and inhibition of binding by various peptides. Peptides 1 and 2 were labeled with a fluorophore at the N-terminus to generate two probes (3, FlupYTPEP, and 4, Flu-TLNSDGpYTPEPA) for the FP assay. In two separate experiments, Cbl(TKB) was titrated into a constant concentration of each probe. The K d values were found to be 2.4 ± 0.1 μM for 3 and 6.2 ± 0.3 μM for 4 ( Table  1) . These direct binding experiments demonstrated that 3 bound with ∼3-fold better affinity than 4.
It is feasible that the fluorescent label at the N-terminus of 3 could replace the extended residue sequence of 4 and contribute to the binding affinity. To rule out this possibility, a set of competitive binding experiments were performed where each peptide was titrated vs a constant concentration of Cbl(TKB) and the fluorescently labeled probe. Titration of 1 and 2 vs 3 showed that the unlabeled pentapeptide bound with ∼6-fold better affinity (Table 1) . Similarly, titration of 1 and 2 vs 4 showed that the unlabeled pentapeptide bound with ∼8-fold better affinity. As expected, the unlabeled peptides were able to competitively compete for binding with the matched labeled probe and with the unmatched labeled probe. The ability of the pentapeptide to displace the 12-mer probe and vice versa support the hypothesis that 1 occupies the same binding site as 2. Moreover, the K i values were comparable when compared across each probe. That is, the change in probe affinity is accounted for when determining the binding constant for the inhibitor (K i ) in a competitive binding experiment.
Next, ITC was used as an orthogonal technique to directly determine Cbl(TKB)−peptide binding. In separate experiments, 1 and 2 were titrated against a solution of Cbl(TKB) and the heat changes of the solution upon binding were measured. These direct binding experiments demonstrated that the short peptide binds Cbl(TKB) with up to ∼5-fold improvement in the K a when compared to the long peptide (Table 1) . These results are consistent with those observed from the FP measurements.
To determine if the higher affinity of pentapeptide 1 vs the 12-mer 2 can translate into better inhibition of the Cbl(TKB) interaction with an intact cellular binding partner, we conducted pull-down experiments with activated epidermal growth factor receptor (EGFR) expressed in an immortal human mammary epithelial cell line 16A5. 31 In a typical experiment, cells were stimulated with EGF, which results in the phosphorylation of EGFR (pEGFR). GST-Cbl(TKB) fusion protein isolated on glutathione-Sepharose beads was used to pull down activated EGFR from lysates of EGFstimulated cells in the absence or presence of increasing concentrations of each peptide. After 1 h of incubation, the beads were spun down, and the bound pEGFR protein was visualized using Western blotting for pTyr. The results from the pull-down experiments are summarized in Figure 2 . As expected, we observed a decrease in the binding of pEGFR with increasing concentrations of the inhibitor peptides. Moreover, 1 has ∼3-fold better IC 50 compared to 2. Together, the biochemical studies clearly show that the computationally predicted pentapeptide 1 binds Cbl(TKB) with about 3-to 8-fold higher affinity compared to the 12-mer peptide 2.
To identify the key residues required for binding within the pentapeptide 1, an alanine scan was performed in which each residue was sequentially replaced with an Ala (15−20) residue. We and others have shown that the phophotyrosine is a key binding component, as the nonphosphorylated Tyr-containing peptide does not bind Cbl(TKB). 6, 7, 29 Analysis of ΔΔG relative to 1 reveals that each residue modestly contributes to Cbl(TKB) binding ( Figure 3A , cyan bars). Interestingly, there is a significant loss of activity in 19, suggesting that the proline residue at the P + 4 position makes substantial contribution to binding. Introduction of a carboxylic acid in place of carboxamide on the C-terminal P + 4 proline also results in a loss of activity in 20, which highlights the hydrophobic nature of the interaction. Taken together, this indicates that 1 is anchored to Cbl(TKB) in a two-point binding fashion. These sites can potentially be exploited to improve inhibition. Furthermore, removal of the acyl group at the N-terminus, in 15, results in a loss of ΔG of ∼2 kcal·mol −1 . This change suggested that there is a possible third anchoring interaction.
Several 12-mer peptides have been identified that bind Cbl(TKB), and the crystal structures of many of these complexes have been solved. 25, 26 On the basis of these reports and our observations, each known Cbl(TKB)-binding peptide was truncated to the corresponding pentapeptide sequences and tested for binding-inhibitory activity ( Figure 3A , white, gray, and black bars). It was observed that those peptides that adopt the same binding mode and orientation as 1 have comparable affinity (21, Figure 3C ). The peptide orientations that deviate slightly lose activity by ∼1 order of magnitude (22−24, Figure 3D ), and the peptide backbones that deviate significantly from 1 have ∼2 orders of magnitude lower activity (25 and 26, Figure 3E ). These results suggest that in addition Figure 2 . Differential competition of pEGFR pull-down by GSTCbl(TKB) in the presence of increasing amounts of (A) 2 or (B) 1 assessed using immunoblotting for pEGFR with an anti-phosphotyrosine antibody 4G10. Negative control peptides do not inhibit the Cbl(TKB) pull-down of pEGFR. Band intensities were quantified using Image-J software and pull-down IC 50 values were determined by nonlinear regression using SigmaPlot. to the contacts made by the phosphate group and the P + 4 Pro residue, the backbone geometry might contribute to Cbl(TKB) binding.
In parallel, we conducted a computational study to determine binding affinities of the peptides in the library depicted in Figure 3 . A plot of the experimentally determined vs the computed binding affinities resulted in an R 2 of 0.68 ( Figure   4A ). This suggests that at least for this system a docking-guided peptidomimetic inhibitor optimization will be reliable. On the basis of the fidelity of our computational studies, we were able to determine the most active binding mode of 1 and overlaid the docked structure onto the crystal structure of 2 ( Figure 4B and Table S4 ). The ΔG Calc of the best conformation was −8.2 kcal·mol −1
. It was observed that when the residues N terminal to the pTyr are removed, the free acyl group can rotate to occupy a shallow pocket situated adjacent to the pTyr binding site ( Figure 4B ). The pocket is composed of residues Arg 299 , Gln 302 , Ile 318 , and His 320 ( Figure S1 ). On the basis of these observations, it seems likely that the N-terminal acyl group of pentapeptide 1 forms a hydrogen bond with the Arg 299 guanidinium group. The Arg 299 side chain is at prime interacting distance of 2.82 Å and oriented in the optimum collinear geometry ( Figure S1 ). This observation is consistent with the resulting loss in affinity when the acyl group is removed ( Figure 3A, peptide 15) . To test this prediction, the oxygen was replaced with a carbon to disrupt hydrogen bond formation, yielding peptide 27 ( Figure S1 ). ΔG Calc was found to be −7.6 kcal·mol −1 (ΔΔG = 0.6 kcal·mol
). 2 results in a loss of ∼1 kcal·mol −1 in binding affinity and is sterically inhibited from occupying the shallow pocket. Together our data suggest that the pocket formed by the residues Arg 299 , Gln 302 , Ile 318 , and His 320 can be exploited to generate inhibitors with higher affinity. This is currently under investigation.
■ CONCLUSION
We have used tandem computational and experimental approaches to identify the minimal peptide unit capable of binding Cbl(TKB). The computational studies predicted that a pentapeptide (1) is sufficient for binding and indicated that it is likely a two-point binding mode. Cell-free assays confirmed the interaction of 1 with Cbl(TKB) in direct binding and competitive inhibition assays. Further, these studies demonstrated that pentapeptide 1 bound with a higher affinity than the 12-mer peptide 2. A pull-down assay with full length proteins revealed that these peptides could inhibit the Cbl(TKB)−protein interaction and that 1 has ∼3-fold better activity than 2, which is consistent with the cell-free binding assays. A SAR study with a small library of pentapeptides indicated that 1 is the minimal unit and that the backbone geometry is important. In parallel, results from a docking study correlated well with the experimental data for the peptide library. Finally, the predicted binding mode of 1 revealed a third point of interaction adjacent to the binding site of the pTyr residue that can be occupied in the absence of the extended Nterminus of 2. The additional H-bond and buried surface could contribute to the observed increase in binding affinity of the pentapeptide compared to the 12-mer peptide. We are currently exploiting these observations to develop high affinity Cbl(TKB) inhibitors that will be reported in due course. Figure 1 ). The coordinates for the truncated peptide were generated using a hybrid docking molecular dynamics simulation, and the graphic was generated using PyMOL. 32 PDB code is 1FBV.
